# What a Receptor Structure Can Explain About PT-141

- Article ID: research-306
- Product: PT-141 (pt-141-449)
- Canonical page: https://heritagebiolabs.com/research-library/articles/306-what-a-receptor-structure-can-explain-about-pt-141
- Product collection: https://heritagebiolabs.com/research-library/products/pt-141
- Product page: https://heritagebiolabs.com/product/pt-141-449
- Reading focus: Mechanisms & biology (Reading focus is a navigational tag, not an evidence grade.)
- Source years: 2021, 2026

> Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend.

A peptide is a short amino-acid chain linked by peptide bonds. The shape of a chain helps determine how it fits into a receptor. Bremelanotide, also called PT-141, is a cyclic peptide in the melanocortin research family. The current US label describes it as a melanocortin receptor agonist. An older direct structural study lets researchers see how it interacted with one member of that family, the melanocortin-4 receptor, or MC4R. [1, 2]

Huibing Zhang and colleagues used cryogenic electron microscopy to observe MC4R in an active complex with a signaling protein. They compared structures obtained with several molecules bound, including a naturally occurring peptide signal, bremelanotide, another peptide drug and a small molecule. Some peptide agonists occupied the receptor in related ways. The small molecule showed a different pattern of interactions. These comparisons help explain how different compounds can activate the receptor without all fitting in exactly the same way. [2]

A receptor structure captures a selected state under study conditions. It can help researchers identify interactions to investigate further. It does not measure a person's desire, distress or response to treatment. It also cannot determine by itself how much a receptor in a given tissue contributes to the clinical response. The label describes melanocortin receptor activity while distinguishing it from an established clinical mechanism for the labeled condition. [1, 2]

The structural paper is included because it directly visualized a complex with bremelanotide. It supplies evidence about binding and signaling at a receptor, alongside a different body of evidence for patient outcomes. Keeping those lines of evidence separate makes both easier to interpret. [1, 2]

## Sources

1. US Food and Drug Administration. Vyleesi (bremelanotide) prescribing information. Drugs@FDA (revised 2026-10). <https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/210557s005lbl.pdf>
2. Zhang H et al. Structural insights into ligand recognition and activation of the melanocortin-4 receptor. Cell Research (online 2021-08-25). <https://pubmed.ncbi.nlm.nih.gov/34433901/>

## Provenance

Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed. Source volume: Peptide Research Articles 062 - PT-141 and RETA GLP-3.docx; article 306; content SHA-256 4586db998d45136f2edc998880b43a53c2c26372c011781ca0c57616de6fc6bf.
